[Advanced credit: patient enrolling and therapy initiation in the ADVANCE trial].
In the new millennium, high blood pressure and diabetes are emerging as one of the greatest threats to the health of populations worldwide. The comanagement of diabetes (hemoglobinA1c < 6.5%), and hypertension (blood pressure <130/80 Hgmm), has become central to the prevention of macro- and microvascular disease in diabetic patients. The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN trial, the first large prospective multicenter randomized controlled trial, uses a factorial 2 x 2 design to determine the effects on macro- and microvascular outcomes of blood pressure lowering (with a perindopril/indapamide combination) and of intensive glucose control using a gliclazide MR based regimen.
Nagy
Viktor
V
Semmelweis Egyetem, Altalános Orvostudományi Kar II. Belgyógyászati Klinika Budapest. nagyvik@bel12.sote.hu
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D048909:Diabetes Complications / Q000097:blood / Q000188:drug therapy*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007190:Indapamide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D020913:Perindopril / Q000627:therapeutic use*; D012107:Research Design; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D001786:Blood Glucose; D005907:Gliclazide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007190:Indapamide; D020913:Perindopril